During the past decade, Montreal Chest Institute conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Montreal Chest Institute" #1 sponsor was "McGill University Health Centre/Research Institute of the McGill University Health Centre" with 7 trials, followed by "Centers for Disease Control and Prevention" with 3 trials sponsored, "Laval University" with 3 trials sponsored, "Abbott" with 2 trials sponsored and "Boston Scientific Corporation" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Montreal Chest Institute" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 7 trials as a collaborator, "CIHR Canadian HIV Trials Network" with 4 trials as a collaborator, "GlaxoSmithKline" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "Takeda" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Montreal Chest Institute" are "HIV Infections" (12 trials), "Chronic Obstructive Pulmonary Disease" (5 trials), "COPD" (4 trials), "Asthma" (3 trials) and "Cystic Fibrosis" (2 trials). Many other conditions were trialed in "Montreal Chest Institute" in a lesser frequency.

Most popular intervention types in "Montreal Chest Institute" are "Drug" (22 trials), "Behavioral" (4 trials), "Device" (4 trials), "Other" (4 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Nelfinavir mesylate" (3 trials), "Lopinavir/Ritonavir" (2 trials), "Ritonavir" (2 trials) and "AGS-004" (1 trials). Other intervention names were less common.

The vast majority of trials in "Montreal Chest Institute" are 31 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Montreal Chest Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Montreal Chest Institute, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Montreal Chest Institute, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 10 trials that are defined as “Not Applicable".